Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Jane Yardley"'
Autor:
Amitabh Dash, Kate Pinner, Yuichi Inoue, Kenichi Hayashida, Sung Chul Lim, Chang-Ho Yun, Tsuo-Hung Lan, Chieh-Liang Huang, Jane Yardley, Naoki Kubota, Margaret Moline
Publikováno v:
Sleep Medicine: X, Vol 4, Iss , Pp 100044- (2022)
Study objectives: Lemborexant (LEM) is a dual orexin receptor antagonist approved for treating adults with insomnia. We analyzed the efficacy (subjective sleep outcomes) and safety of LEM over 12 months in the subgroup of Asian subjects from Study E2
Externí odkaz:
https://doaj.org/article/a8c72a7e621a4ab98e20c02d82cd3b54
Autor:
Jane Yardley, Henning Adamek
Publikováno v:
Info Diabetologie. 17:32-39
Publikováno v:
Monday, April 24.
Autor:
Thomas Roth, Russell Rosenberg, Charles M. Morin, Jane Yardley, Kate Pinner, Carlos Perdomo, Norman Atkins, Elizabeth Pappadopulos, Manoj Malhotra, Margaret Moline
Publikováno v:
Sleep Medicine. 90:249-257
Evaluate changes in insomnia severity in subjects with moderate to severe insomnia (Insomnia Severity Index [ISI] score ≥15) treated for 12 months nightly with lemborexant.This phase 3 randomized study comprised two 6-month treatment periods. In Pe
Publikováno v:
SLEEP. 46:A159-A160
Introduction The Insomnia Severity Index (ISI) is a 7-item self-reported questionnaire evaluating perception of symptom severity included in Phase 3 studies of lemborexant (LEM), a competitive dual orexin receptor antagonist approved in several count
Publikováno v:
Journal of the Endocrine Society. 6:A379-A380
Background Patients with diabetes report sleep problems more often than healthy individuals. Notably, ∼50% of the patients with Type 2 diabetes have reported insomnia. However, literature on the efficacy and safety of commonly prescribed sleep prom
Publikováno v:
Canadian Journal of Diabetes. 46:S32-S33
Autor:
Yuichi Inoue, Kohei Ishikawa, Gleb Filippov, Carlos Perdomo, Margaret Moline, Mikko Kärppä, Jane Yardley, Kate Pinner, Naoki Kubota
Publikováno v:
Sleep Medicine. 80:333-342
Objective/background Lemborexant is a dual orexin receptor antagonist approved in the United States, Japan, and Canada for the treatment of insomnia in adults. We report effectiveness and safety outcomes in subjects with insomnia who received up to t
Autor:
Craig Chepke, Rakesh Jain, Russell Rosenberg, Margaret Moline, Jane Yardley, Kate Pinner, Dinesh Kumar, Carlos Perdomo, Gleb Filippov, Norman Atkins, Manoj Malhotra
Publikováno v:
Postgraduate medicine. 134(3)
Fatigue is a common symptom in patients with insomnia. This analysis evaluated whether treatment of nighttime symptoms of insomnia with a dual orexin receptor antagonist, lemborexant, might also reduce fatigue.Analyses were conducted of two phase 3 s
Autor:
Robin Pokrzywinski, Cristina Abel, William R Lenderking, Jane Yardley, Jocelyn Cheng, Margaret Moline
Publikováno v:
Alzheimer's & Dementia. 17